217 related articles for article (PubMed ID: 37547340)
1.
Pagliarin LG; de Oliveira LM; Dos Anjos VNF; de Souza CBT; Peiter GC; Façanha Wendel C; Dillmann Groto A; Freire de Melo F; Teixeira KN
World J Biol Chem; 2023 Jul; 14(4):72-83. PubMed ID: 37547340
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 liver and gastroenterology findings: An
Peiter GC; de Souza CBT; de Oliveira LM; Pagliarin LG; Dos Anjos VNF; da Silva FAF; de Melo FF; Teixeira KN
World J Hepatol; 2022 Jun; 14(6):1131-1141. PubMed ID: 35978663
[TBL] [Abstract][Full Text] [Related]
3. Molecular docking of DS-3032B, a mouse double minute 2 enzyme antagonist with potential for oncology treatment development.
da Mota VHS; Freire de Melo F; de Brito BB; da Silva FAF; Teixeira KN
World J Clin Oncol; 2022 Jun; 13(6):496-504. PubMed ID: 35949428
[TBL] [Abstract][Full Text] [Related]
4.
Vieira RV; Peiter GC; de Melo FF; Zarpelon-Schutz AC; Teixeira KN
World J Clin Oncol; 2024 May; 15(5):653-663. PubMed ID: 38835850
[TBL] [Abstract][Full Text] [Related]
5. Pea eggplant (
Govender N; Zulkifli NS; Badrul Hisham NF; Ab Ghani NS; Mohamed-Hussein ZA
PeerJ; 2022; 10():e14168. PubMed ID: 36518265
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and greener pastures biological study of bis-thiadiazoles as potential Covid-19 drug candidates.
Said MA; Riyadh SM; Al-Kaff NS; Nayl AA; Khalil KD; Bräse S; Gomha SM
Arab J Chem; 2022 Sep; 15(9):104101. PubMed ID: 35845755
[TBL] [Abstract][Full Text] [Related]
7. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
Wakchaure PD; Ghosh S; Ganguly B
J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493
[TBL] [Abstract][Full Text] [Related]
8. Molecular optimization, docking, and dynamic simulation profiling of selective aromatic phytochemical ligands in blocking the SARS-CoV-2 S protein attachment to ACE2 receptor: an
Dey D; Paul PK; Al Azad S; Al Mazid MF; Khan AM; Sharif MA; Rahman MH
J Adv Vet Anim Res; 2021 Mar; 8(1):24-35. PubMed ID: 33860009
[TBL] [Abstract][Full Text] [Related]
9. In silico-based Approach to Investigate the Ability of PEGylated Rapamycin to Inhibit Galectin-3.
Abdelkarim Maki MA; Kumar PV; Elumalai M; Bayazeid O
Curr Drug Discov Technol; 2021; 18(3):451-456. PubMed ID: 31969105
[TBL] [Abstract][Full Text] [Related]
10. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and molecular dynamics simulation studies of quinoline derivatives as protease inhibitors against SARS-CoV-2.
Singh VK; Chaurasia H; Kumari P; Som A; Mishra R; Srivastava R; Naaz F; Singh A; Singh RK
J Biomol Struct Dyn; 2022; 40(21):10519-10542. PubMed ID: 34253149
[TBL] [Abstract][Full Text] [Related]
12. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
[TBL] [Abstract][Full Text] [Related]
13. In silico discovery of 3 novel quercetin derivatives against papain-like protease, spike protein, and 3C-like protease of SARS-CoV-2.
Bhattacharya K; Bordoloi R; Chanu NR; Kalita R; Sahariah BJ; Bhattacharjee A
J Genet Eng Biotechnol; 2022 Mar; 20(1):43. PubMed ID: 35262828
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of defensins as neutralizing agents against the deadly SARS-CoV-2.
Deepthi V; Mohanakumar KP; Rajamma U
J Biomol Struct Dyn; 2023 Apr; 41(7):2911-2925. PubMed ID: 35189779
[TBL] [Abstract][Full Text] [Related]
15. Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19.
Rehman MT; AlAjmi MF; Hussain A
Curr Pharm Des; 2021; 27(33):3577-3589. PubMed ID: 33200697
[TBL] [Abstract][Full Text] [Related]
16. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
17. Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach.
Singh SK; Upadhyay AK; Reddy MS
3 Biotech; 2021 Feb; 11(2):93. PubMed ID: 33520579
[TBL] [Abstract][Full Text] [Related]
18. Identification of Cyanobacteria-Based Natural Inhibitors Against SARS-CoV-2 Druggable Target ACE2 Using Molecular Docking Study, ADME and Toxicity Analysis.
Sahu N; Mishra S; Kesheri M; Kanchan S; Sinha RP
Indian J Clin Biochem; 2023 Jul; 38(3):361-373. PubMed ID: 35812791
[TBL] [Abstract][Full Text] [Related]
19. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic and Therapeutic Potential Zinc Metallodrugs Drug Discovery: Identification of SARS-CoV-2 Replication and Spike/ACE2 Inhibitors.
Ngoepe MP; Tapala KC; Clayton HS
Curr Comput Aided Drug Des; 2022; 18(7):519-534. PubMed ID: 36154578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
